• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种有望用于发展中国家暴露后预防的狂犬病疫苗，一种在中国生产的纯化Vero细胞疫苗。

Promising rabies vaccine for postexposure prophylaxis in developing countries, a purified vero cell vaccine produced in china.

作者信息

Wang Chuanlin, Zhang Xiaowei, Song Qingkun, Tang Kun

机构信息

Emergency Department, Peking University People's Hospital, Beijing 100044, People's Republic of China.

出版信息

Clin Vaccine Immunol. 2010 Apr;17(4):688-90. doi: 10.1128/CVI.00433-09. Epub 2010 Feb 10.

DOI:10.1128/CVI.00433-09
PMID:20147495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2849343/
Abstract

We evaluated the immunogenicity, safety, and antibody persistence of a Vero cell rabies vaccine manufactured in China, compared with those of Verorab. Adequate titers of antibody were observed for the two vaccines. ChengDa rabies vaccine could be a promising alternative vaccine for many developing countries which cannot afford expensive rabies vaccines.

摘要

我们评估了一种中国生产的Vero细胞狂犬病疫苗与Verorab相比的免疫原性、安全性和抗体持久性。两种疫苗均观察到足够的抗体滴度。对许多买不起昂贵狂犬病疫苗的发展中国家来说，成大狂犬病疫苗可能是一种有前景的替代疫苗。

相似文献

1
Promising rabies vaccine for postexposure prophylaxis in developing countries, a purified vero cell vaccine produced in china.一种有望用于发展中国家暴露后预防的狂犬病疫苗，一种在中国生产的纯化Vero细胞疫苗。
Clin Vaccine Immunol. 2010 Apr;17(4):688-90. doi: 10.1128/CVI.00433-09. Epub 2010 Feb 10.
2
A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).鸭胚纯化疫苗（PDEV，Vaxirab）与鸡胚纯化疫苗（PCEC，Rabipur）和vero 细胞狂犬病疫苗（PVRV，Verorab）的安全性和免疫原性比较研究。
Vaccine. 2009 Dec 10;28(1):148-51. doi: 10.1016/j.vaccine.2009.09.090. Epub 2009 Oct 8.
3
A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.在中国，健康儿童和成年人按照接触后程序接种时，新一代、无血清、高度纯化的 Vero 细胞狂犬病疫苗具有良好的安全性，其免疫原性与对照疫苗 Verorab®相当。
Vaccine. 2013 Dec 5;31(50):5940-7. doi: 10.1016/j.vaccine.2013.10.043. Epub 2013 Oct 19.
4
Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.使用 vero 细胞抗狂犬病疫苗进行暴露后预防 5 年后狂犬病抗体的持续存在情况以及对单次加强剂量的抗体反应。
Clin Vaccine Immunol. 2011 Sep;18(9):1477-9. doi: 10.1128/CVI.05090-11. Epub 2011 Jul 13.
5
Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis.两种冻干vero 细胞狂犬病疫苗用于人接触后预防的安全性和免疫原性。
Vaccine. 2011 Mar 24;29(15):2679-81. doi: 10.1016/j.vaccine.2011.01.053. Epub 2011 Feb 3.
6
A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.一种无血清、纯化的vero 细胞狂犬病疫苗在健康成年人中的暴露前使用是安全的，与参考疫苗 Verorab 一样具有免疫原性：一项随机对照的 II 期临床试验结果。
Vaccine. 2013 Apr 26;31(18):2295-301. doi: 10.1016/j.vaccine.2013.02.058. Epub 2013 Mar 16.
7
Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.皮内暴露后狂犬病疫苗接种用纯化 Vero 细胞狂犬病疫苗：在菲律宾一项随机非劣效性试验中，比较一周 4 部位方案与泰国红十字会更新方案。
Vaccine. 2019 Apr 10;37(16):2268-2277. doi: 10.1016/j.vaccine.2019.02.083. Epub 2019 Mar 16.
8
Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine.小剂量皮内注射纯化鸡胚细胞狂犬病疫苗或纯化Vero细胞狂犬病疫苗后暴露后患者的抗体反应。
Bull World Health Organ. 2000;78(5):693-8.
9
Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.一种新型经色谱纯化的Vero细胞狂犬病疫苗（CPRV）用于暴露后狂犬病预防的免疫原性和有效性：菲律宾的一项两阶段随机临床试验
Acta Trop. 2000 Feb 25;75(1):39-52. doi: 10.1016/s0001-706x(99)00092-3.
10
Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.色谱纯化vero 细胞狂犬病疫苗用于皮内暴露前和暴露后狂犬病预防的安全性和免疫原性。
Expert Rev Vaccines. 2014 Dec;13(12):1593-601. doi: 10.1586/14760584.2014.971764. Epub 2014 Oct 15.

引用本文的文献

1
Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10-60 years in China.在萨格勒布和埃森方案下冻干人用狂犬病疫苗（Vero 细胞）的安全性、免疫原性和免疫持久性：在中国健康 10-60 岁人群中进行的一项随机、开放标签、对照的 III 期临床试验。
Front Immunol. 2024 Nov 7;15:1444686. doi: 10.3389/fimmu.2024.1444686. eCollection 2024.
2
A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10-60 Years Following Essen and Zagreb Vaccination Procedures.一项随机、双盲、对照的III期临床试验，旨在评估冻干人用狂犬病疫苗（Vero细胞）在10至60岁健康参与者中按照埃森和萨格勒布接种程序接种后的免疫原性和安全性。
Vaccines (Basel). 2023 Aug 1;11(8):1311. doi: 10.3390/vaccines11081311.
3
Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial.在接触后人群中按萨格勒布和埃森方案接种冻干纯化vero 细胞狂犬病疫苗的安全性、免疫原性：上市后、平行对照临床试验。
Hum Vaccin Immunother. 2021 Aug 3;17(8):2547-2553. doi: 10.1080/21645515.2021.1880200. Epub 2021 Feb 25.
4
Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.在暴露后人群中，采用萨格勒布方案或埃森方案接种纯化 vero 细胞培养狂犬病疫苗（Speeda）后的免疫原性、安全性及抗体持久性。
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-8. doi: 10.1080/21645515.2017.1279770. Epub 2017 Jan 25.
5
Animal-associated exposure to rabies virus among travelers, 1997-2012.1997 - 2012年旅行者中与动物相关的狂犬病病毒暴露情况
Emerg Infect Dis. 2015 Apr;21(4):569-77. doi: 10.3201/eid2104.141479.
6
Challenges and needs for China to eliminate rabies.中国消除狂犬病的挑战和需求。
Infect Dis Poverty. 2013 Oct 2;2(1):23. doi: 10.1186/2049-9957-2-23.
7
Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.使用 vero 细胞抗狂犬病疫苗进行暴露后预防 5 年后狂犬病抗体的持续存在情况以及对单次加强剂量的抗体反应。
Clin Vaccine Immunol. 2011 Sep;18(9):1477-9. doi: 10.1128/CVI.05090-11. Epub 2011 Jul 13.

本文引用的文献

1
Canine vaccination--providing broader benefits for disease control.犬类疫苗接种——为疾病控制带来更广泛益处。
Vet Microbiol. 2006 Oct 5;117(1):43-50. doi: 10.1016/j.vetmic.2006.04.009. Epub 2006 Apr 18.
2
Preventing the incurable: Asian rabies experts advocate rabies control.预防无法治愈之症：亚洲狂犬病专家倡导狂犬病防控。
Vaccine. 2006 Apr 12;24(16):3045-9. doi: 10.1016/j.vaccine.2005.10.015.
3
The role of veterinary epidemiology in the study of free-roaming dogs and cats.兽医流行病学在流浪狗和猫研究中的作用。
Prev Vet Med. 2001 Mar 29;48(4):273-86. doi: 10.1016/s0167-5877(00)00201-4.
4
Prevalence and control of zoonotic diseases: collaboration between public health workers and veterinarians in Burkina Faso.人畜共患病的流行与防控：布基纳法索公共卫生工作者与兽医之间的合作
Acta Trop. 2000 Jul 21;76(1):53-7. doi: 10.1016/s0001-706x(00)00090-5.
5
Developments in the production and application of rabies vaccine for human use in China.中国用于人类的狂犬病疫苗的生产与应用进展
Trop Doct. 2000 Jan;30(1):14-6. doi: 10.1177/004947550003000108.
6
Round table on epidemiology and control of fox rabies.狐狸狂犬病流行病学与防控圆桌会议
Vet Microbiol. 1992 Nov;33(1-4):297-301. doi: 10.1016/0378-1135(92)90057-z.
7
WHO Expert Committee on Rabies.世界卫生组织狂犬病专家委员会
World Health Organ Tech Rep Ser. 1992;824:1-84.
8
A microtest for the quantitation of rabies virus neutralizing antibodies.
J Biol Stand. 1979 Jul;7(3):213-20. doi: 10.1016/s0092-1157(79)80024-4.